St. Jude Medical is announcing American and European regulatory approvals of the Angio-Seal™ Evolution Vascular Closure Device, a product that, as the company promises, will make the life of cardiologists, radiologists, vascular surgeons, and others who go endovascular, easier. In addition to instant hemostasis, the device allows vascular closure with one handed operation, promises decreased number of complications, earlier ambulation, and even higher patient satisfaction. And you thought that patients could care less about their femoral region!
From the press release:
The Angio-Seal Evolution device is designed to enable physicians to quickly and effectively seal femoral artery punctures made during minimally invasive catheter-based procedures. Effectively sealing the puncture helps achieve hemostasis (cessation of bleeding) quickly, enabling the patient to walk and resume activities sooner.
The Angio-Seal Evolution platform features an entirely new delivery system that significantly reduces the variability that can occur as physicians deploy and secure the Angio-Seal closure system. Consistent with its Angio-Seal predecessors, Angio-Seal Evolution achieves hemostasis through the deployment of an anchor, suture and collagen seal (each of which is bioabsorbable). With Evolution, however, single-handed deployment has been made possible for the first time, which enables physicians to more easily support the puncture site. The new device’s automated collagen compaction system ensures consistent compaction of the collagen against the exterior wall of the vessel reducing procedural variables. With fewer variables in device deployment, physicians gain greater control and consistency in achieving rapid, safe and reliable hemostasis for their patients.
Press release: St. Jude Medical Announces U.S. and European Approval of Angio-Seal Evolution Vascular Closure Device
Product page: Angio-Seal™ Evolution™
Product brochure (.pdf)…
Flashback: Angio-Seal: A VIP in Cardiac Cath
